Loading...

Micro-X

ASX:MX1
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MX1
ASX
A$50M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Micro-X has significant price volatility in the past 3 months.
MX1 Share Price and Events
7 Day Returns
1.5%
ASX:MX1
0.7%
AU Medical Equipment
1.7%
AU Market
1 Year Returns
-5.7%
ASX:MX1
-1%
AU Medical Equipment
5.9%
AU Market
MX1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Micro-X (MX1) 1.5% 20% 24.5% -5.7% -24.1% -
AU Medical Equipment 0.7% 3.1% 0.1% -1% 44.1% 106.9%
AU Market 1.7% 4% 8.6% 5.9% 21.4% 7.4%
1 Year Return vs Industry and Market
  • MX1 underperformed the Medical Equipment industry which returned -1% over the past year.
  • MX1 underperformed the Market in Australia which returned 5.9% over the past year.
Price Volatility
MX1
Industry
5yr Volatility vs Market

MX1 Value

 Is Micro-X undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Micro-X is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Micro-X has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Micro-X. This is due to cash flow or dividend data being unavailable. The share price is A$0.33.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Micro-X's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Micro-X's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:MX1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.12
ASX:MX1 Share Price ** ASX (2019-04-24) in AUD A$0.33
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Micro-X.

ASX:MX1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MX1 Share Price ÷ EPS (both in AUD)

= 0.33 ÷ -0.12

-2.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Micro-X is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Micro-X is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Micro-X's expected growth come at a high price?
Raw Data
ASX:MX1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
104.3%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Micro-X, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Micro-X's assets?
Raw Data
ASX:MX1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.00
ASX:MX1 Share Price * ASX (2019-04-24) in AUD A$0.33
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.78x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.66x
ASX:MX1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MX1 Share Price ÷ Book Value per Share (both in AUD)

= 0.33 ÷ 0.00

-288.71x

* Primary Listing of Micro-X.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Micro-X has negative assets, we can't compare the value of its assets to the AU Medical Equipment industry average.

Next steps:

  1. Take a look at Micro-X's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Micro-X's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Medical Equipment industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Micro-X's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Micro-X has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MX1 Future Performance

 How is Micro-X expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
104.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Micro-X expected to grow at an attractive rate?
  • Micro-X's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Micro-X's earnings growth is expected to exceed the Australia market average.
  • Micro-X's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:MX1 Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:MX1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 104.3%
ASX:MX1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 114.9%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:MX1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:MX1 Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 68 2 16 1
2020-06-30 17 -8 -5 1
2019-06-30 4 -7 -10 1
ASX:MX1 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -9 -18
2018-09-30 2 -9 -17
2018-06-30 2 -8 -17
2018-03-31 1 -9 -14
2017-12-31 1 -11 -11
2017-09-30 1 -11 -12
2017-06-30 1 -11 -13
2017-03-31 1 -10 -13
2016-12-31 1 -9 -13
2016-09-30 1 -11 -12
2016-06-30 1 -13 -11
2016-03-31 1 -10 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Micro-X's earnings are expected to grow significantly at over 20% yearly.
  • Micro-X's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:MX1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Micro-X Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MX1 Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.09 0.09 0.09 1.00
2020-06-30 -0.03 -0.03 -0.03 1.00
2019-06-30 -0.07 -0.07 -0.07 1.00
ASX:MX1 Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.12
2018-09-30 -0.12
2018-06-30 -0.11
2018-03-31 -0.10
2017-12-31 -0.08
2017-09-30 -0.09
2017-06-30 -0.10
2017-03-31 -0.09
2016-12-31 -0.11
2016-09-30 -0.10
2016-06-30 -0.17
2016-03-31 -0.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Micro-X will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Micro-X's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Micro-X has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MX1 Past Performance

  How has Micro-X performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Micro-X's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Micro-X does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Micro-X's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Micro-X's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Micro-X's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Micro-X Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MX1 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.77 -17.94 6.40
2018-09-30 1.69 -17.27 5.98
2018-06-30 1.61 -16.60 5.56
2018-03-31 1.35 -13.62 5.01
2017-12-31 1.10 -10.64 4.63
2017-09-30 0.88 -11.78 4.27
2017-06-30 0.66 -12.92 3.92
2017-03-31 0.81 -12.72 3.57 -4.03
2016-12-31 0.97 -12.51 3.23 -8.06
2016-09-30 0.93 -11.63 2.63 -4.03
2016-06-30 0.89 -10.74 2.03
2016-03-31 0.59 -11.75 1.37 6.47
2015-12-31 0.28 -12.76 0.70 12.94
2015-09-30 0.18 -11.46 0.58 10.03
2015-06-30 0.07 -10.16 0.46 7.13
2014-06-30 -0.39 0.14 0.30
2013-06-30 0.08 0.00 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Micro-X has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Micro-X has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Micro-X improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Micro-X's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Micro-X has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MX1 Health

 How is Micro-X's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Micro-X's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Micro-X is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Micro-X's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Micro-X's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Micro-X has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Micro-X Company Filings, last reported 3 months ago.

ASX:MX1 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -0.17 6.75 4.38
2018-09-30 -0.17 6.75 4.38
2018-06-30 -0.73 9.60 4.07
2018-03-31 -0.73 9.60 4.07
2017-12-31 10.53 3.00 4.10
2017-09-30 10.53 3.00 4.10
2017-06-30 15.32 3.00 5.58
2017-03-31 15.32 3.00 5.58
2016-12-31 11.20 2.80 5.60
2016-09-30 11.20 2.80 5.60
2016-06-30 18.23 0.00 4.17
2016-03-31 18.23 0.00 4.17
2015-12-31 23.04 0.00 18.36
2015-09-30 23.04 0.00 18.36
2015-06-30 -10.28 15.41 2.59
2014-06-30 -0.38 0.24 0.04
2013-06-30
  • Micro-X has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Micro-X's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Micro-X has less than a year of cash runway based on current free cash flow.
  • Micro-X has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year.
X
Financial health checks
We assess Micro-X's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Micro-X has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MX1 Dividends

 What is Micro-X's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Micro-X dividends. Estimated to be 0% next year.
If you bought A$2,000 of Micro-X shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Micro-X's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Micro-X's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:MX1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.2%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:MX1 Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.00 1.00
2020-06-30 0.00 1.00
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Micro-X has not reported any payouts.
  • Unable to verify if Micro-X's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Micro-X's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Micro-X has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Micro-X's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Micro-X's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Micro-X afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Micro-X has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MX1 Management

 What is the CEO of Micro-X's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Rowland
COMPENSATION A$321,085
TENURE AS CEO 4.6 years
CEO Bio

Mr. Peter Robin Rowland, BSc., MBA, MIET, CEng, FAICD, serves as Managing Director and Executive Director of Micro-X Limited. Mr. Rowland is a laser industry veteran with 25 years' experience in engineering design, development and project management of innovative, high technology military and scientific equipment at BAE Systems. He worked in the engineering design, development and project management of innovative, high-technology military & scientific equipment in his early career in Scotland. In Australia, he ran an engineering design consultancy group, was Director of Business Development at BAE Systems. He served as Managing Director and Vice President of BIOLASE, Inc. (formerly, Biolase Technology, Inc.) since March 2006 and also served as its Vice President of Asia Pacific Operations. Prior to BIOLASE, he served as the Chief Executive Officer and President of Ellex Medical Pty Ltd. He served as Managing Director and Director of Ellex Medical Lasers Limited until November 4, 2002.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is about average for companies of similar size in Australia.
Management Team

Peter Rowland

TITLE
MD & Executive Director
COMPENSATION
A$321K
TENURE
4.6 yrs

Georgina Carpendale

TITLE
CFO & Company Secretary
COMPENSATION
A$158K
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure of the Micro-X board of directors in years:

3.7
Average Tenure
  • The tenure for the Micro-X board of directors is about average.
Board of Directors

Patrick O'Brien

TITLE
Non Executive Chairman
COMPENSATION
A$76K
TENURE
3.7 yrs

Peter Rowland

TITLE
MD & Executive Director
COMPENSATION
A$321K
TENURE
4.6 yrs

Alexander Gosling

TITLE
Non-Executive Director
COMPENSATION
A$50K
TENURE
3.7 yrs

David Peter Symons

TITLE
Non-Executive Director
COMPENSATION
A$50K
TENURE
3.7 yrs

Yasmin King

TITLE
Non-Executive Director
COMPENSATION
A$64K
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Micro-X's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Micro-X has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MX1 News

Simply Wall St News

When Will Micro-X Limited (ASX:MX1) Breakeven?

Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. … With the latest financial year loss of -AU$16.6m and a trailing-twelve month of -AU$17.9m, the AU$52m market-cap amplifies its loss by moving further away from its breakeven target. … See our latest analysis for Micro-X

Simply Wall St -

What Kind Of Shareholders Own Micro-X Limited (ASX:MX1)?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of AU$51m, Micro-X is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Micro-X Limited's (ASX:MX1) CEO Being Overpaid?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Peter Rowland's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Micro-X Limited has a market cap of AU$37m, and is paying total annual CEO compensation of AU$321k.

Simply Wall St -

Such Is Life: How Micro-X Shareholders Saw Their Shares Drop 51%

Unfortunately, they have held through a 51% decline in the share price in that time. … Given that Micro-X didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … The share price has moved in quite the opposite direction, down 21% over that time, a bad result.

Simply Wall St -

Are Micro-X Limited (ASX:MX1) Shareholders Getting A Good Deal?

I’ve analysed below, the health and outlook of Micro-X’s cash flow, which will help you understand the stock from a cash standpoint. … What is free cash flow. … Micro-X’s free cash flow (FCF) is the level of cash flow the business generates from its operational activities, after it reinvests in the company as capital expenditure.

Simply Wall St -

Micro-X Limited (ASX:MX1): Time For A Financial Health Check

While small-cap stocks, such as Micro-X Limited (ASX:MX1) with its market cap of AU$44.75m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Want To Invest In Micro-X Limited (ASX:MX1)? Here's How It Performed Lately

After reading Micro-X Limited's (ASX:MX1) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … How Did MX1's Recent Performance Stack Up Against Its Past. … MX1 is loss-making, with the most recent trailing twelve-month earnings of -AU$10.64m (from 31 December 2017), which compared to last year has become.

Simply Wall St -

Loss-Making Micro-X Limited (ASX:MX1) Expected To Breakeven

Many investors are wondering the rate at which MX1 will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for MX1, its year of breakeven and its implied growth rate. … ASX:MX1 Past Future Earnings May 16th 18 Underlying developments driving MX1’s growth isn’t the focus of this broad overview, though, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Simply Wall St -

Are Micro-X Limited's (ASX:MX1) Interest Costs Too High?

As the purpose of this article is a high-level overview, I won’t be looking at this today, but you can assess some of MX1’s operating efficiency ratios such as ROA here. … MX1’s level of debt is appropriate relative to its total equity, at 28.50%. … Investors' risk associated with debt is very low with MX1, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: MX1’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Are Earnings Prospects Improving For Loss-Making Micro-X Limited's (ASX:MX1)?

See our latest analysis for Micro-X Commentary On MX1's Past Performance For the most up-to-date info, I use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For Micro-X, its most recent earnings (trailing twelve month) is -AU$10.64M, which, relative to last year’s level, has become less negative. … This means although Micro-X is currently unprofitable, whatever recent headwind the industry is enduring, Micro-X is relatively better-cushioned than its peers.What does this mean?

Simply Wall St -

MX1 Company Info

Description

Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers Carestream DRX Revolution Nano, an ultra-lightweight digital mobile X-ray system for use in hospital wards and intensive care units. It is also developing Mobile Backscatter Imager, a small lightweight system for stand-off imaging of improvised explosive devices, as well as Rover for use in military medical facilities. The company was founded in 2011 and is based in Tonsley, Australia.

Details
Name: Micro-X Limited
MX1
Exchange: ASX
Founded: 2011
A$50,080,172
151,758,099
Website: http://www.micro-x.com
Address: Micro-X Limited
A14, 6 MAB Eastern Promenade,
1284 South Road,
Tonsley,
South Australia, 5042,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MX1 Ordinary Shares Australian Securities Exchange AU AUD 22. Dec 2015
Number of employees
Current staff
Staff numbers
0
Micro-X employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 10:35
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.